Press news Biocartis Group NV Biocartis Receives EUR 1.2 million Grant for Development of Highly Innovative Idylla GeneFusion Assay

Nachrichtenquelle: globenewswire
30.09.2020, 07:00  |  107   |   |   

PRESS RELEASE: 30 September 2020, 07:00 CEST
                                                                                                           

Biocartis Receives EUR 1.2 million Grant for Development of Highly Innovative Idylla GeneFusion Assay

Mechelen, Belgium, 30 September 2020 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that it has received a EUR 1.2 million grant from VLAIO, the Flanders organization for Innovation & Entrepreneurship, for the development of the highly innovative GeneFusion Assay on its easy, rapid molecular and fully automated diagnostics platform Idylla.

The Idylla GeneFusion Assay will include a highly multiplexed panel of established and emerging biomarkers, and will be the first FFPE1 RNA2-based assay on the Idylla platform. The Idylla GeneFusion Assay is expected to bring results in approx. 3 hours, with less than 2 minutes hands-on time. The VLAIO grant is intended to support the development of the GeneFusion Assay on the Idylla platform, and to support related research studies on different sample and tumor tissue types, including on lung cancer tissue.

Lung cancer is the most common cause of cancer-related deaths worldwide (27%) with 1.7 million deaths annually3. Clinical non-small cell lung cancer (NSCLC) guidelines4 recommend testing for amongst others EGFR mutations5. Today, gene fusions represent an increasingly important biomarker test category6. Although detected in a small portion of NSCLCs, testing for these gene fusions is important for the identification of patients who may benefit from different fusion gene targeted therapies, which show high response rates and long disease control upon treatment7. Current testing methods however are cumbersome because different technologies8 are needed to test all required biomarkers. Additionally, sample quantity and quality to perform all these tests are commonly suboptimal. Due to these complexities, time to results can be delayed, which can lead to inappropriate treatment decisions.

Seite 1 von 4
BIOCARTIS GROUP Aktie jetzt ab 0€ handeln - auf Smartbroker.de



Diesen Artikel teilen

0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

Meistgelesene Nachrichten des Autors

Titel
Titel
Titel
Titel

Diskussionen zu den Werten

ZeitTitel
06.10.20